StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for AZTR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.19 | $0.18 | -4.76% | 0.8M |
| 05-18 | $0.19 | $0.19 | +2.26% | 0.6M |
| 05-19 | $0.19 | $0.19 | -0.31% | 0.4M |
| 05-20 | $0.19 | $0.20 | +3.68% | 0.8M |
| 05-21 | $0.20 | $0.21 | +8.72% | 0.7M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $7.50K |
Operating Income | $-10.97M | $-8.74M | $-5.97M | $-10.99M |
Net Income | $-10.96M | $-8.72M | $-2.89M | $-8.97M |
EPS (Diluted) | $-2.25 | $-3.06 | $-0.40 | $-15.70 |
Total Assets | $5.03M | $4.30M | $3.96M | $7.36M |
Total Liabilities | $1.22M | $2.02M | $1.73M | $1.66M |
Cash & Equivalents | $2.07M | $1.40M | $1.05M | $4.55M |
Free Cash Flow OCF − CapEx | $-11.25M | $-8.35M | $-5.90M | $-10.19M |
Shares Outstanding | 10.74M | 5.60M | 17.98M | 1.15M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.